0001209191-21-008229.txt : 20210205
0001209191-21-008229.hdr.sgml : 20210205
20210205174924
ACCESSION NUMBER: 0001209191-21-008229
CONFORMED SUBMISSION TYPE: 5
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201231
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 5
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 21597577
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
5
1
doc5.xml
FORM 5 SUBMISSION
X0306
5
2020-12-31
0
0
1
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2020-08-27
4
L
0
75
3.28
A
24967
D
Common Stock
2020-08-28
4
L
0
75
3.24
A
25042
D
Common Stock
2020-08-31
4
L
0
75
3.25
A
25117
D
Common Stock
2020-09-01
4
L
0
75
3.24
A
25192
D
Common Stock
2020-09-02
4
L
0
75
3.32
A
25267
D
Common Stock
2020-09-03
4
L
0
75
3.35
A
25342
D
Common Stock
2020-09-04
4
L
0
75
3.29
A
25417
D
Common Stock
2020-09-08
4
L
0
75
3.22
A
25492
D
Common Stock
2020-09-09
4
L
0
75
3.28
A
25567
D
Common Stock
2020-09-10
4
L
0
75
3.34
A
25642
D
Common Stock
2020-09-11
4
L
0
75
3.36
A
25717
D
Common Stock
2020-09-14
4
L
0
75
3.41
A
25792
D
Common Stock
2020-09-15
4
L
0
75
3.41
A
25867
D
Common Stock
2020-09-16
4
L
0
75
3.41
A
25942
D
Common Stock
2020-09-17
4
L
0
75
3.41
A
26017
D
Common Stock
2020-09-18
4
L
0
75
3.41
A
26092
D
Common Stock
2020-09-21
4
L
0
75
3.37
A
26167
D
Common Stock
2020-09-22
4
L
0
75
3.36
A
26242
D
Common Stock
2020-09-23
4
L
0
75
3.31
A
26317
D
Common Stock
2020-09-24
4
L
0
75
3.19
A
26392
D
Common Stock
2020-09-25
4
L
0
75
3.31
A
26467
D
Common Stock
2020-09-28
4
L
0
75
3.27
A
26542
D
Common Stock
2020-09-29
4
L
0
75
3.26
A
26617
D
Common Stock
2020-09-30
4
L
0
75
3.26
A
26692
D
Common Stock
2020-10-01
4
L
0
75
3.29
A
26767
D
Common Stock
2020-10-02
4
L
0
75
3.33
A
26842
D
Common Stock
2020-10-05
4
L
0
75
3.35
A
26917
D
Common Stock
2020-10-06
4
L
0
75
3.35
A
26992
D
Common Stock
2020-10-07
4
L
0
75
3.24
A
27067
D
Common Stock
2020-10-08
4
L
0
75
3.24
A
27142
D
The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
Filing 1 of 3
Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact
2021-02-05